Got $200? 4 Ridiculously Cheap Stocks You Can Buy Now
Summary
Parkev provides a strategic overview for investors with limited capital, emphasizing that a low share price does not necessarily equate to a good deal. Parkev explains the methodology of using a customized discounted cash flow (DCF) model to determine a stock's fair value. By comparing this intrinsic value to the current market price, Parkev identifies opportunities where the market is mispricing businesses relative to their long-term potential.
The thesis focuses on four companies across different sectors:
Mentioned Stocks
Reasoning: Parkev states that SoFi is undervalued with a fair value of $19.86 compared to its $17 market price. Parkev likes the shift toward an asset-light strategy where SoFi originates and sells loans rather than holding them, reducing risk while maintaining growth.
Reasoning: Parkev calculates a fair value of $36.69 for DraftKings, while it currently trades at $24.32. Parkev believes the company will benefit from future regulation that targets prediction market competitors who are currently bypassing state-by-state regulatory frameworks.
Reasoning: Parkev identifies Chewy as an attractive buy at $22, given a fair value calculation of $33.55. Parkev highlights that 80% of sales come from recurring subscriptions, allowing for highly efficient inventory and logistics management.
Reasoning: Parkev views Clorox as significantly undervalued, with a fair value of $140 against a market price of $96. Parkev argues that while consumers are currently trading down to generic brands, the long-term strength of the business makes this a rare value opportunity for investors.